Appendix 4C - quarterly
Released
Released
Announcement PDF
29 October 2015
Resonance Health Ltd (ASX:RHT) Appendix 4C – 1st Quarter Cash Flow Report
Resonance Health Limited today released its 1st quarter Cash Flow Report for the period ending 30
September 2015.
Cash at 30 September 2015 was $2.787million. Receipts from customers for the September quarter
was $605,000 and an R&D Tax Incentive of $116,000 was received.
The marketing spend in the September quarter was $151,000. Marketing continues to be focused
and targeted towards key opinion leaders, patient disease associations and pharmaceutical drug
companies.
During the quarter the Company:
x
x
x
x
x
Appointed a new distributor in Canada
Held a celebration with St Mary’s Hospital (London, UK) to mark their milestone of 1000
FerriScans
Established FerriScan on a mobile MR scanner in the UK
Promoted FerriScan at the Annual Conference of the Sickle Cell Disease Association of
America
Travelled to Vietnam to speak at the Thalassaemia International Federation Pan-Asian
Conference on Haemoglobinopathies
Research and development spend was in line with our planned budget of $123,000 focused on further
studies involving HepaFat-Scan and the development of a non-invasive liver fibrosis measurement
technology.
During the quarter:
x
x
x
x
The Company further refined its expertise in bone marrow iron assessments and has been
actively discussing an opportunity to provide these measurements in a small pharmaceutical
sponsored study
The AASLD abstract for the Company’s prototype liver fibrosis measurement technology was
th
accepted. The abstract will be presented at the annual Liver Meeting which begins 13
November 2015
The first patient was recruited for the clinical study to assess whether HepaFat-Scan can
improve post-surgical outcomes when applied prior to liver surgery for the treatment of
colorectal metastases
The Company’s partnership with CSIRO continued as we work with them to apply some of
their expertise as part of our ongoing development of a non-invasive liver fibrosis
measurement
The Company was also pleased to see our Chief Scientific Officer, Prof Tim St Pierre, receive the
award for the Western Region EY Entrepreneur of the Year (Technology category).
Investors can subscribe to our ASX market releases via our web site.
http://www.resonancehealth.com/investors/asx-subscribe.html
For further information please contact:
Resonance Health
Adrian Bowers
Company Secretary
T: +61 8 9286 5300
E: adrianb@resonancehealth.com
+ See chapter 19 for defined terms.
Appendix 4C Page 1
Appendix 4C
Quarterly report for entities
admitted on the basis of commitment
Rule 4.7B
Appendix 4C
Quarterly report
for entities admitted
on the basis of commitments
Introduced 31/3/2000. Amended 30/9/2001
Name of entity
Resonance Health Limited
ABN
Quarter ended (“current quarter”)
96 006 762 492
30 September 2015
Consolidated statement of cash flows
Cash flows related to operating activities
1.1
1.2
1.3
1.4
1.5
1.6
1.7
Receipts from customers
Payments for
(a) staff costs
(b) advertising and marketing
(c) research and development
(d) leased assets
(e) other working capital
Dividends received
Interest and other items of a similar nature
received
Interest and other costs of finance paid
Income taxes (paid)/received
Other Receipts/Payments (a) consulting &
professional services
(b) statutory & compliance
(c) grants
(d) Due diligence expense
Current quarter
$A’000
Year to date
$A’000
605
(311)
(151)
(123)
(119)
20
605
(311)
(151)
(123)
(119)
20
116
(8)
116
(8)
(47)
(18)
(47)
(18)
Net operating cash flows
+ See chapter 19 for defined terms.
Appendix 4C Page 2
Appendix 4C
Quarterly report for entities
admitted on the basis of commitment
1.8
1.9
Current quarter
Year to date
$A’000
$A’000
Net operating cash flows (carried forward)
Cash flows related to investing activities
Payment for acquisition of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current assets
(e) other non-current assets
Proceeds from disposal of:
(a) businesses (item 5)
(b) equity investments
(c) intellectual property
(d) physical non-current
assets
(e) other non-current assets
(9)
-
(9)
-
-
-
-
-
-
-
Net investing cash flows
(9)
(9)
1.14
Total operating and investing cash flows
(27)
(27)
1.15
1.16
1.17
1.18
1.19
1.20
Cash flows related to financing activities
Proceeds from issues of shares, options, etc.
Proceeds from sale of forfeited shares
Proceeds from borrowings
Repayment of borrowings
Dividends paid
Other (costs of capital raising)
-
-
Net financing cash flows
-
-
Net increase (decrease) in cash held
(27)
(27)
1.21
1.22
Cash at beginning of quarter/year to date
Exchange rate adjustments to item 1.20
2,797
17
2,797
17
1.23
Cash at end of quarter
2,787
2,787
1.10
1.11
1.12
1.13
Loans to other entities
Loans repaid by other entities
Other (Cash introduced on acquisition of
controlled entity)
+ See chapter 19 for defined terms.
Appendix 4C Page 3
Appendix 4C
Quarterly report for entities
admitted on the basis of commitment
Payments to directors of the entity and associates of the directors
Payments to related entities of the entity and associates of the related entities
Current quarter
$A'000
1.24
Aggregate amount of payments to the parties included in item 1.2
1.25
Aggregate amount of loans to the parties included in item 1.11
1.26
Explanation necessary for an understanding of the transactions
$35k
-
$35K – Directors fees
Non-cash financing and investing activities
2.1
Details of financing and investing transactions which have had a material effect on consolidated
assets and liabilities but did not involve cash flows
N/A.
2.2
Details of outlays made by other entities to establish or increase their share in businesses in which
the reporting entity has an interest
N/A
Financing facilities available
Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).
Amount available
$A’000
Amount used
$A’000
3.1
Loan facilities
-
-
3.2
Credit standby arrangements
-
-
+ See chapter 19 for defined terms.
Appendix 4C Page 4
Appendix 4C
Quarterly report for entities
admitted on the basis of commitment
Reconciliation of cash
Reconciliation of cash at the end of the quarter (as
shown in the consolidated statement of cash flows) to
the related items in the accounts is as follows.
4.1
Cash on hand and at bank
4.2
Deposits at call
4.3
Bank overdraft
4.4
Other (provide details)
Current quarter
$A’000
- Term deposits
Total: cash at end of quarter (item 1.22)
Previous quarter
$A’000
537
537
-
-
-
-
2,250
2,250
2,787
2,787
Acquisitions and disposals of business entities
Acquisitions
(Item 1.9(a))
5.1
Name of entity
5.2
5.4
Place of incorporation
or registration
Consideration for
acquisition or disposal
Total net assets
5.5
Nature of business
5.3
Disposals
(Item 1.10(a))
N/A
N/A
Compliance statement
1
This statement has been prepared under accounting policies which comply with
accounting standards as defined in the Corporations Act (except to the extent that
information is not required because of note 2) or other standards acceptable to ASX.
2
This statement does give a true and fair view of the matters disclosed.
Adrian Bowers
Company Secretary
+ See chapter 19 for defined terms.
Appendix 4C Page 5
Share your feedback
Discover